Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2022 Aug 30:10.1111/pin.13267. Online ahead of print. doi: 10.1111/pin.13267

An autopsy case of fulminant myocarditis after severe acute respiratory syndrome coronavirus 2 vaccine inoculation

Hidetoshi Satomi 1,2,6, Harutaka Katano 3, Hiroyuki Kanno 2,, Mikiko Kobayashi 2,7, Yukari Ohkuma 4, Naoto Hashidume 4, Tatsuya Usui 4, Shunichi Tsukada 5, Ichiro Ito 1
PMCID: PMC9537995  PMID: 36040128

Abstract

A 61‐year‐old woman without significant medical history developed fever 3 days after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination and went into shock the next day. She was negative for SARS‐CoV‐2 mRNA in real‐time polymerase chain reaction (PCR). Finally, she died 10 days after vaccination. At autopsy, the heart showed moderate dilatation of both ventricles, and the myocardium showed an uneven color change and decreased elasticity. Histologically, severe myocarditis with extensive myocytolysis was observed. The myocarditis showed severe inflammatory cell infiltration with T‐lymphocyte and macrophage predominance, and in addition to the inflammatory cells described above, vast nuclear dust accompanying neutrophilic infiltration was observed. In the bone marrow and lymph nodes, hemophagocytosis was observed. In postmortem examination, nucleic acids of any cardiotropic viruses including SARS‐CoV‐2 were not detected using multivirus real‐time PCR system. We discussed the relationship between the possible immune reaction after vaccination and the myocarditis observed in this case from immunopathological viewpoints. This mRNA vaccine is the first applied nucleic acid vaccine for humans, and its mechanism of efficacy and immune acquisition remain unclear. We hope the accumulation of more detailed analyses of the similar cases to reveal the mechanism of this kind of adverse reaction.

Keywords: cytotoxic T‐cells, hypercytokinemia, myocarditis, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination


Abbreviations

COVID‐19

coronavirus disease 2019

CTLs

cytotoxic T‐cells

LNP

lipid nanoparticle

SARS‐CoV‐2

severe acute respiratory syndrome coronavirus 2

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in December 2019, causing a respiratory disease pandemic named coronavirus disease 2019 (COVID‐19). The spread of this infection has become a global public health problem, and the spread of COVID‐19 has triggered international efforts to accelerate vaccine development and vaccination on a global scale. 1

The need for vaccine development has led to the establishment of several SARS‐CoV‐2 vaccine candidates. One of the candidates is a messenger RNA vaccine, which encodes a SARS‐CoV‐2 spike glycoprotein and is expected to confer immunity. 2 Initially, this vaccine was considered to be safe, but adverse events due to vaccine administration have been reported. Most of the adverse events were mild and transient reactions, such as fatigue, chills, headache, myalgia, and pain at the injection site. However, some cases of potentially serious reactions, such as myocarditis, have been reported. 3 , 4 The incidence of myocarditis after mRNA vaccination was higher in younger males, and the severity of myocarditis reported was mostly mild to moderate, and most of the patients were discharged with the improvement of symptoms. 5 , 6 However, a fatal case has been reported, suggesting that it is an adverse event that should be recognized. 7 At present, the accumulation of cases is small, and the association between vaccination and myocarditis is largely unknown.

Here we report an autopsy case of a 61‐year‐old woman who developed fulminant myocarditis and died after her first vaccination.

CLINICAL SUMMARY

The patient was a 61‐year‐old woman with no medical history of note. Three days after her first inoculation of the SARS‐CoV‐2 vaccine (PfizerBioNTech mRNA vaccine BNT162b2), she developed a fever of 39°C and general malaise and was admitted to a nearby hospital. She was negative for SARS‐CoV‐2 mRNA by real‐time polymerase chain reaction (PCR) analysis using nasopharyngeal swab. Laboratory examinations revealed the elevation of brain natriuretic peptide (625.3 pg/mL; normal range < 100 pg/mL) and creatine kinase (CK) (603 IU/L; normal range < 197 IU/L). The day after her admission, CK further rose to 62 049 IU/L and CK‐MB was 398 IU/L (normal range < 12 IU/L). She became pulseless and went into shock. Echocardiogram revealed the ejection fraction of left ventricle had decreased from 54% to 0% during one day after admission. An urgent coronary angiography was performed, but there was no significant narrowing of the coronary arteries. Cardiogenic shock due to acute myocarditis was suspected, and she had received hydrocortisone (200 mg/day) for 5 days. Extracorporeal circulation using intra‐aortic balloon pumping and percutaneous cardiopulmonary support and extracorporeal pacing were used to support her circulation, but her self‐beating gradually disappeared, and she became dependent on extracorporeal pacing. Six days after inoculation, she went into shock again. Ten days after vaccination, she was transferred to Nagano Red Cross Hospital to receive further circulation assistance. Despite using a cardiac pump catheter for supplemental circulation, she was unable to maintain her blood pressure and died within the day. An autopsy was performed.

The investigation was conducted in accordance with the Declaration of Helsinki of 1975. This case report was exempt from the Institutional Ethics Review Board standard at Nagano Red Cross Hospital. Informed consent for the present study was obtained from the patient's bereaved family.

PATHOLOGICAL FINDINGS

The patient was a female corpse with severe subcutaneous edema, serous pleural effusion (left, 500 mL; right, 500 mL), ascites (400 mL), and pericardial effusion (150 mL). At autopsy, the heart weighed 450 g and was mildly enlarged.

The left ventricles were slightly dilated, and the wall elasticity was decreased. The myocardium showed heterogeneous color tone, indicating mild fibrosis in the antero‐septal area (Figure 1a). Coronary arteries exhibited slight atherosclerosis without apparent stenosis. Histologically, extensive myocytolysis was observed, with severe inflammatory cell infiltration and edema (Figure 1c). The inflammatory infiltrates adjacent to the damaged cardiomyocytes were predominantly lymphocytes and macrophages (Figure 1c). Contraction band necrosis was absent. Fibrotic change corresponding to the whitish color change in macroscopic findings was not confirmed in the antero‐septal area. On the other hand, there was slight fibrosis predominantly in the perivascular area (Figure 1d), which might suggest presence of certain cardiac risk factor. Eosinophils were rarely observed and giant cells were not observed in myocarditis lesion (Figure 1e). Microthrombi were absent. The lesion exhibited the focal, geographical, and transmural distribution, in part, and affected throughout the myocardial layer (Figure 1b). The myocarditis lesion also involved conduction system, however, the infiltration of inflammatory cells was a little milder. Immunohistochemistry showed diffuse infiltration of PG‐M1‐positive cells (Figure 2a), with CD3‐positive cells (Figure 2b) predominating over CD20‐positive cells (results not shown). There were many more CD8‐positive cells than CD4‐positive cells (Figure 2c,d). In addition to lymphocytes and macrophages, vast nuclear dust accompanying neutrophilic infiltration was observed (Figure 1f). Mild fibrosis and slight infiltration of lymphocytes and macrophages were observed in the epicardium, confirming the diagnosis of pericarditis (results not shown).

Figure 1.

Figure 1

Gross and histological findings of the heart. (a) Cross‐section of the heart. The heart shows mild dilation of the left ventricle and color change of the wall indicating mild fibrosis in the antero‐septal area. (b–f) Histopathology of the myocardium. Hematoxylin and eosin (b, c, e, and f) and elastica‐Goldner (d) staining. There is diffuse infiltration of inflammatory cells throughout myocardium (b). Infiltrating inflammatory cells are mainly lymphocytes and macrophages, with vast nuclear dust (c). There is also mild perivascular fibrosis in myocardium (d). In addition to mononuclear cells, few eosinophils are observed (arrowhead) (e). Vast nuclear dust is easily identified, and a few neutrophils are also observed (arrowheads) (f). (b and d, scale bar is 500 μm; c, e, and f, scale bar is 50 μm).

Figure 2.

Figure 2

Immunohistochemistry of infiltrating inflammatory cells of the heart (a, PG‐M1; b, CD3; c, CD4; d, CD8). Infiltrating cells are predominantly PG‐M1‐positive or CD3‐positive cells, with a predominance of CD8‐positive cells (a–d, scale bar is 100 μm).

In the subpleural region of the lungs, hemorrhagic infarcts were observed (Figure 3a), and small fibrin thrombi were visible in the lumen of the pulmonary arteries (Figure 3b). Centrilobular necrosis of the liver (Figure 3c), acute tubular necrosis of the kidney (results not shown), and severe pulmonary congestion (Figure 3a) were observed, and there were consistent findings in various organs of the body as changes associated with biventricular heart failure due to myocarditis. There was no evidence of diffuse alveolar damage in the lung. Erythrophagocytosis was seen in the bone marrow (Figure 3d) and lymph nodes (results not shown).

Figure 3.

Figure 3

Histological findings of the other organs (a and b, lung; c, liver; d, bone marrow). (a) Hematoxylin and eosin staining. Scattered hemorrhagic infarction in the lung and severe pulmonary congestion are visible. (b) Hematoxylin and eosin staining. Tiny fibrin thrombi are visible in the pulmonary artery lumen. (c) Elastica‐Goldner staining. Centrilobular necrosis is visible. (d) Hematoxylin and eosin staining. Hemophagocytosis (arrowheads) is visible (a, scale bar is 1000 μm; b, scale bar is 50 μm; c, scale bar is 200 μm; d, scale bar is 50 μm).

DISCUSSION

The current case is an autopsy case of a 61‐year‐old woman who had a rapid course of illness to death after her first inoculation of the SARS‐CoV‐2 vaccine. Published information of heart pathology of the illness of after SARS‐CoV‐2 vaccination is small. The infiltration of eosinophils in addition to T‐cells and macrophages is noted in two case of myocarditis after SARS‐CoV‐2 vaccination, 7 although infiltrating eosinophils were very few in our case. In two adolescent autopsy cases following the second SARS‐CoV‐2 mRNA vaccine dose, the histopathology revealed the myocardial injury resembling a catecholamine‐inducing injury which exhibits contraction band necrosis and/or myocytolysis with interstitial and perivascular infiltration of inflammatory cells consisting of predominantly neutrophils and macrophages and distributing separately from damaged cardiomyocytes. 8 However, in our case, the infiltrating inflammatory cells were predominantly T‐cells and macrophages and showed diffuse infiltration with adjacent damaged cardiomyocytes. Therefore, the histopathology and also the mechanisms in myocardial injury after SARS‐CoV‐2 vaccination seem to be heterogeneous.

Myocarditis with transmural myocardial necrosis was consistent with the cause of cardiogenic shock and death. One of the causes of myocarditis is a viral infection. Unfortunately, the antibodies to the viruses which might cause myocarditis were not evaluated in the current case. Histologically, viral myocarditis has been reported to have an inflammatory picture with the infiltration of macrophages and cytotoxic T‐cells (CTLs). 9 In the current case, infiltration of PG‐M1‐positive cells and CD8‐positive cells was noticeable. In addition, there were hemophagocytic images in the bone marrow and lymph nodes, suggesting the coexistence of hypercytokinemia. Based on these histological findings, the possibility of viral myocarditis was initially considered. However, nucleic acids of any cardiotropic viruses including SARS‐CoV‐2 were not detected in formalin‐fixed and paraffin‐embedded and fresh‐frozen samples of the heart using multivirus real‐time PCR system. 10 Furthermore, the following clinicopathological features would not be consistent with viral myocarditis.

First, the current case fell into a shock four days after vaccination. If the same pathologic change observed at autopsy is responsible for the patient's shock at 4 days after vaccination, the infiltration of CD8‐positive CTLs would be a little earlier histological change compared with the standard time course of the primary immune response. It takes about 5 days for naive T‐cells to differentiate into CTLs. 11 Borrow et al. reported that in immune responses to lymphocytic choriomeningitis virus in mice, the number of CD8‐positive cells reaches a peak about one week after infection. 12 The patient's condition began to worsen 3 days after the first inoculation of the vaccine, and over the next few days, the course of the disease became fatal. On the third day after vaccination, organ damage appeared, and the patient died without improvement in her general condition. The autopsy showed findings of myocarditis with extensive infiltration of CTLs. This clinical course suggests that CTL‐mediated myocarditis had already presented at her first attack of shock condition. Therefore, we considered the possibility of cross‐immunity or immune memory as a mechanism for the early expansion of CTLs. Multiple independent assays have shown that anti‐SARS‐CoV‐2 antibodies are also present in coronavirus‐uninfected individuals. 13 Mateus et al. found that a fraction of memory CD4‐positive T‐cells cross‐react with both SARS‐CoV‐2 antigens and coronavirus antigens, with which people are routinely infected. 14 These results suggest that memory helper T‐cells to conventional coronavirus antigens may have triggered a rapid immune response at the time of vaccination, and the infiltration of CTLs may have been conspicuous for the time course. However, none of the reports currently examine the antigenic similarity between the conventional coronavirus and the spike protein produced by vaccination, and we had not analyzed this aspect.

Second, the conspicuous presence of vast nuclear debris accompanying neutrophilic infiltration in the myocardium is atypical for viral myocarditis. Vast nuclear debris suggests the activation of neutrophils, due to such as antineutrophil cytoplasmic antibodies, however, these antibodies were negative with less than sensitivity (data not shown). Although we could not rule out the possibility that the myocardial ischemia due to low output syndrome causes neutrophilic infiltration and subsequent nuclear debris formation, we also considered the possibility that the lipid nanoparticle (LNP) in the vaccine caused neutrophilic infiltration and nuclear dust formation. LNP is a substance that is added to the vaccine during SARS‐CoV‐2 vaccination to ensure that mRNA is efficiently introduced into the body. 15 There is an experimental report in mice that innate immunity, including neutrophils, was elicited when LNP was administered alone. 16 These effects of LNP may explain the reaction of neutrophilic infiltration and activation observed in the histology slides of the heart. However, there have been no reports on the pharmacokinetics of LNP in humans. Therefore, it is challenging to clarify the relationship between LNP and neutrophil infiltration in the current case.

Therefore, it may be possible that the myocarditis observed in this case was developed through a condition different from viral infection. Although SARS‐CoV‐2 vaccination has an extremely favorable risk ratio for myocarditis and should be recommended in adolescent and adult populations, 17 the SARS‐CoV‐2 vaccine is the first mRNA vaccine and there remain many unanswered questions.

In this case, thrombus formation was observed in the arterial lumen of the peripheral lung tissue, and pulmonary infarction was observed. It has been reported that the spike protein produced after SARS‐CoV‐2 vaccination may induce endothelial damage and thrombus formation through the ACE2 receptor. 18 Based on this report, micro thrombosis in the lumen of the pulmonary artery and pulmonary infarction can be explained as changes due to endothelial damage caused by spike proteins.

The clinicopathological findings of the current case might shed light on the pathogenesis of myocarditis possibly induced by inoculation of SARS‐CoV‐2 mRNA vaccine, and give suggestions in the direction of further research. We hope the accumulation of detailed immunological and histopathological analyses of similar cases in the near future.

AUTHOR CONTRIBUTIONS

Hidetoshi Satomi performed the autopsy and histological evaluation and drafted the manuscript and figures. Harutaka Katano performed nucleic acid analysis and review of the manuscript; Hiroyuki Kanno, Mikiko Kobayashi, and Ichiro Ito performed histological evaluation and review of the manuscript. Yukari Ohkuma, Naoto Hashidume, Tatsuya Usui, and Shunichi Tsukada performed the evaluation of clinical data and review of the manuscript.

CONFLICT OF INTEREST

None declared.

ACKNOWLEDGMENT

The authors thank Dr. Yuichiro Hirata for technical assistance in the examination of nucleic acids in pathologic specimens.

Satomi H, Katano H, Kanno H, Kobayashi M, Ohkuma Y, Hashidume N, et al. An autopsy case of fulminant myocarditis after severe acute respiratory syndrome coronavirus 2 vaccine inoculation. Pathol Int. 2022;1–6. 10.1111/pin.13267

REFERENCES

  • 1. World Health Organization (homepage on the internet). Genève; World Health Organization. Coronavirus disease 2019 (‎COVID‐19)‎: situation report‐94; cited 2021 December 12. Available from: https://apps.who.int/iris/bitstream/handle/10665/331865/nCoVsitrep23Apr2020-eng.pdf
  • 2. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer‐BioNTech COVID‐19 vaccine ‐ United States, December 2020. Morb Mortal Wkly Rep. 2020;69:1922–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis following COVID‐19 vaccination. Radiol Case Rep. 2021;16:2142–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Dionne A, Sperotto F, Chamberlain S, Baker AL, Powell AJ, Prakash A, et al. Association of myocarditis with BNT162b2 messenger RNA COVID‐19 vaccine in a case series of children. JAMA Cardiol. 2021;6:1446–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid‐19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID‐19 mRNA vaccines. Circulation. 2021;144:471–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Verma AK, Lavine KJ, Lin C‐Y. Myocarditis after Covid‐19 mRNA vaccination. N Engl J Med. 2021;385:1332–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Gill JR, Tashjian R, Duncanson E. Autopsy histopathologic cardiac findings in two adolescents following the second COVID‐19 vaccine dose. Arch Pathol Lab Med. 2022. Aug 1;146:923. 10.5858/arpa.2022-0154-LE [DOI] [PubMed] [Google Scholar]
  • 9. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno‐Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48. [DOI] [PubMed] [Google Scholar]
  • 10. Katano H, Kano M, Nakamura T, Kanno T, Asanuma H, Sata T. A novel real‐time PCR system for simultaneous detection of human viruses in clinical samples from patients with uncertain diagnoses. J Med Virol. 2011;83:322–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Oakes SA. Diseases of the immune system. In: Kumar V, Abbas AK, Aster JC eds. Robbins and Cotran pathologic basis of disease. 10th ed. Philadelphia: Elsevier; 2021. p. 189–266 [Google Scholar]
  • 12. Borrow P, Tough DF, Eto D, Tishon A, Grewal IS, Sprent J, et al. CD40 ligand‐mediated interactions are involved in the generation of memory CD8+ cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J Virol. 1998;72:7440–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS‐CoV‐2 in humans. Science. 2020;370:1339–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross‐reactive SARS‐CoV‐2 T‐cell epitopes in unexposed humans. Science. 2020;370:89–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Granados‐Riveron JT, Aquino‐Jarquin G. Engineering of the current nucleoside‐modified mRNA‐LNP vaccines against SARS‐CoV‐2. Biomed Pharmacother. 2021;142:111953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Ndeupen S, Qin Z, Jacobsen S, Estanbouli H, Bouteau A, Igyártó BZ. The mRNA‐LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. bioRxiv . 2021. 10.1101/2021.03.04.430128 [DOI] [PMC free article] [PubMed]
  • 17. Heymans S, Cooper LT. Myocarditis after COVID‐19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol. 2022;19:75–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, et al. SARS‐CoV‐2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021;128:1323–6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Pathology International are provided here courtesy of Wiley

RESOURCES